Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and...
Gordon
L I
LI
D000082:Acetaminophen / Q000009:adverse effects* / Q000493:pharmacokinetics; D000470:Alkaloids / Q000009:adverse effects; D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D002417:Cattle; D002418:Cattle Diseases / Q000209:etiology; D000075202:Contraindications; D004727:Endothelium / Q000187:drug effects; D005609:Free Radicals; D000079982:Gemtuzumab; D005978:Glutathione / Q000378:metabolism; D018380:Hematopoietic Stem Cell Transplantation; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced* / Q000503:physiopathology / Q000662:veterinary; D006801:Humans; D008099:Liver / Q000166:cytology / Q000187:drug effects; D016686:Monocrotaline / Q000633:toxicity; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D019172:Transplantation Conditioning / Q000009:adverse effects
D000470:Alkaloids; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D005609:Free Radicals; D000082:Acetaminophen; D016686:Monocrotaline; D000079982:Gemtuzumab; D005978:Glutathione